Chromadex ( (CDXC) ) has shared an update.
ChromaDex Corporation has onboarded Ozan Pamir as the new Chief Financial Officer, effective October 21, 2024. Bringing a wealth of experience from his previous role as CFO of 180 Life Sciences and a background in investment banking, Pamir is set to steer ChromaDex’s financial strategy and shareholder value creation. His appointment, announced in a recent press release, is part of the company’s push towards a new phase of development in the NAD+ research and healthy aging sector. Pamir’s compensation includes a $400,000 base salary, potential bonuses, and stock options, with provisions for continued salary upon termination without cause.
For a thorough assessment of CDXC stock, go to TipRanks’ Stock Analysis page.
